Page last updated: 2024-10-30

edaravone and Colonic Inertia

edaravone has been researched along with Colonic Inertia in 1 studies

Colonic Inertia: Symptom characterized by the passage of stool once a week or less.

Research Excerpts

ExcerptRelevanceReference
"An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS)."9.69Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. ( Aoki, M; Apple, S; Bidani, S; Couratier, P; Genge, A; Hirai, M; Jackson, CE; Kalin, A; Lunetta, C; Pattee, GL; Petri, S; Sakata, T; Salah, A; Selness, D; Sobue, G; Wamil, A; Yoshino, H, 2023)
"An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS)."5.69Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. ( Aoki, M; Apple, S; Bidani, S; Couratier, P; Genge, A; Hirai, M; Jackson, CE; Kalin, A; Lunetta, C; Pattee, GL; Petri, S; Sakata, T; Salah, A; Selness, D; Sobue, G; Wamil, A; Yoshino, H, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Genge, A2
Pattee, GL2
Sobue, G2
Aoki, M2
Yoshino, H2
Couratier, P2
Lunetta, C2
Petri, S2
Selness, D2
Bidani, S2
Hirai, M2
Sakata, T2
Salah, A2
Apple, S2
Wamil, A2
Kalin, A2
Jackson, CE2

Trials

1 trial available for edaravone and Colonic Inertia

ArticleYear
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Muscle & nerve, 2023, Volume: 67, Issue:2

    Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male;

2023
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Muscle & nerve, 2023, Volume: 67, Issue:2

    Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male;

2023
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Muscle & nerve, 2023, Volume: 67, Issue:2

    Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male;

2023
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Muscle & nerve, 2023, Volume: 67, Issue:2

    Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male;

2023